Printer Friendly

Dr. Reddy's unveils PRAMIPEXOLE Dihydrochloride Extended-Release Tablets in the US market.

M2 EQUITYBITES-August 13, 2015-Dr. Reddy's unveils PRAMIPEXOLE Dihydrochloride Extended-Release Tablets in the US market

(C)2015 M2 COMMUNICATIONS http://www.m2.com

Pharmaceutical company Dr. Reddy's Laboratories (NYSE:RDY) revealed on Wednesday the availability of the US Food & Drug Administration (USFDA) approved PRAMIPEXOLE dihydrochloride extended-release tablets 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg in the US market on 11 August 2015.

The company said the PRAMIPEXOLE dihydrochloride extended-release tablets 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg is the therapeutic equivalent generic version of MIRAPEX ER (pramipexole dihydrochloride) Extended-Release Tablets.

According to IMS Health, the MIRAPEX ER brand and generic had US sales of about USD48.3m MAT for the most recent 12 months ending in June 2015.

In conjunction, the company's PRAMIPEXOLE dihydrochloride extended-release tablets mg are available in 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg in bottle count sizes of 30.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Aug 13, 2015
Words:177
Previous Article:RXi announces Q2 2015 results.
Next Article:Alibaba Group's net income up by 148% in quarter ended 30 June 2015.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters